

Ms Anjuli Sinniah Senior Adviser, Listings Compliance ASX Limited Level 40, Central Park 152-158 St Georges Terrace Perth WA 6000 23 April 2019

By Email:

ListingsCompliancePerth@asx.com.au

tradinghaltsperth@asx.com.au

Dear Ms Sinniah

ADMEDUS LTD (ASX:AHZ) - EXTENSION FOR VOLUNTARY SUSPENSION

Admedus Limited (the **Company**) refers to the voluntary suspension granted on 17 April 2019 in relation to the share sale agreement entered into by its wholly owned subsidiary Admedus Investments Pty Ltd (**AIPL**) and the other shareholders of Admedus Vaccines Pty Ltd (**Admedus Vaccines**) for the sale of all of the shares of Admedus Vaccines (the **Immunotherapies Transaction**). The Company has today made an announcement concerning the conclusion of the Immunotherapies Transaction.

Notwithstanding the Company's announcement today, pursuant to Listing Rule 17.2, the Company requests a further extension to the voluntary suspension of the quotation of its ordinary securities.

The Company advises that:

- (a) the voluntary suspension is necessary for the Company to finalise the next phase of the Company's recapitalisation plan;
- (b) the Company expects the suspension to last until the earlier of the commencement of normal trading on 7 May 2019, or the release of an announcement by the Company;
- (c) the Company is not aware of any reason why its securities should not be suspended from quotation; and
- (d) the Company is not aware of any further information necessary to inform the market about the voluntary suspension.

Yours sincerely

Steve Denaro

Company Secretary

Admedus Limited

Registered Office:

Toowong Tower, Level 3, 9 Sherwood Rd, Toowong, Queensland 4066

Customer Service:

T: 1300 550 310 F: 1300 880 398 International: T: +61 (0)7 3152 3200 F: +61 (0)7 3152 3299

E: info@admedus.com W: admedus.com